(R)-N-[3-[2-[2-(3-methylindazol-6-yloxy)ethylamino]-1-hydroxyethyl]phenyl]methanesulfonamide hydrochloride | 519158-31-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-N-[3-[2-[2-(3-methylindazol-6-yloxy)ethylamino]-1-hydroxyethyl]phenyl]methanesulfonamide hydrochloride
• 英文别名: N-[3-[(1R)-1-hydroxy-2-[2-[(3-methyl-2H-indazol-6-yl)oxy]ethylamino]ethyl]phenyl]methanesulfonamide;hydrochloride
• CAS: 519158-31-7
• 化学式: C₁₉H₂₄N₄O₄S*ClH
• 分子量: 440.951
• InChiKey: KOJHOKNXULHZBB-FYZYNONXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.37
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  125
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (R)-N-[3-[2-[2-(1-benzyl-3-methylindazol-6-yloxy)ethylamino]-1-hydroxyethyl]phenyl]methanesulfonamide 在 20% palladium hydroxide on carbon 盐酸 、 氢气 、 氨 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 生成 (R)-N-[3-[2-[2-(3-methylindazol-6-yloxy)ethylamino]-1-hydroxyethyl]phenyl]methanesulfonamide hydrochloride
  参考文献：
  名称：

  BICYCLIC COMPOUND

  摘要：

  公开号：

  EP1447400B1

文献信息

• Bicyclic compound
  申请人：Miyoshi Shiro

  公开号：US20050020602A1

  公开（公告）日：2005-01-27

  A compound represented by the general formula I: I wherein R1 represents hydrogen, etc. R 2 represents NHSO 2 R 3 , etc., provided that R 3 represents C 1-6 alkyl, etc. R 5 represents hydrogen, etc. R 6 and R 7 may be the same or different and each independently represents hydrogen, etc. X represents oxygen, etc. Y represents oxygen, etc. Z 1 to Z 6 each represents carbon, etc. n is an integer of 0 to 6 and ast1 indicates that the carbon atom is asymmetric, and *2, in the case where R 5 is not hydrogen, indicates that the carbon atom is asymmetric or a salt of the compound.

  化合物的通式为I：I，其中R1代表氢等，R2代表NHSO2R3等，但R3代表C1-6烷基等，R5代表氢等，R6和R7可以相同也可以不同，且各自独立地代表氢等，X代表氧等，Y代表氧等，Z1至Z6各自代表碳等，n为0至6的整数，ast1表示碳原子是不对称的，*2表示当R5不是氢时，碳原子是不对称的或化合物的盐。
• Indole compounds as B3 androceptor agonist
  申请人：Miyoshi Shiro

  公开号：US20080076815A1

  公开（公告）日：2008-03-27

  Compounds of the general formula (I): or a salt thereof, wherein R 1 is a hydrogen atom or the like; R 2 is NHSO 2 R 3 or the like; R 3 is a (C 1 -C 6 )alkyl group or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 may be the same or different and are each independently a hydrogen atom or the like; X is an oxygen atom or the like; Y is an oxygen atom or the like; Z 1 to Z 6 are a carbon atom or the like; n is an integer of 0 to 6; *1 is an asymmetric carbon atom; and *2 is an asymmetric carbon atom when R 5 is other than a hydrogen atom.

  通式(I)的化合物或其盐，其中R1是氢原子或类似物；R2是NHSO2R3或类似物；R3是(C1-C6)烷基或类似物；R5是氢原子或类似物；R6和R7可以相同或不同，且各自独立地是氢原子或类似物；X是氧原子或类似物；Y是氧原子或类似物；Z1至Z6是碳原子或类似物；n是0到6的整数；*1是不对称碳原子；当R5不是氢原子时，*2是不对称碳原子。
• INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST
  申请人：Miyoshi Shiro

  公开号：US20080015242A1

  公开（公告）日：2008-01-17

  Compounds of the general formula (I): or a salt thereof, wherein R 1 is a hydrogen atom or the like; R 2 is NHSO 2 R 3 or the like; R 3 is a (C 1 -C 6 )alkyl group or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 may be the same or different and are each independently a hydrogen atom or the like; X is an oxygen atom or the like; Y is an oxygen atom or the like; Z 1 to Z 6 are a carbon atom or the like; n is an integer of 0 to 6; *1 is an asymmetric carbon atom; and *2 is an asymmetric carbon atom when R 5 is other than a hydrogen atom.

  通式（I）的化合物或其盐，其中R1是氢原子或类似物；R2是NHSO2R3或类似物；R3是（C1-C6）烷基或类似物；R5是氢原子或类似物；R6和R7可以相同也可以不同，分别是氢原子或类似物；X是氧原子或类似物；Y是氧原子或类似物；Z1到Z6是碳原子或类似物；n是0到6的整数；*1是不对称碳原子；当R5不是氢原子时，*2是不对称碳原子。
• Bicyclic compounds
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP1935882A1

  公开（公告）日：2008-06-25

  Compounds of the general formula (I): or a salt thereof, wherein R1 is a hydrogen atom or the like; R2 is NHSO2R3 or the like; R3 is a (C1-C6)alkyl group or the like; R5 is a hydrogen atom or the like; R6 and R7 may be the same or different and each independently represents a hydrogen atom or the like; X is an oxygen atom or the like; Y is an oxygen atom or the like; Z1 to Z6 are a carbon atom or the like; n is an integer of 0 to 6; * 1 is an asymmetric carbon atom; and *2 is an asymmetric carbon atom when R5 is other than a hydrogen atom.

  通式 (I) 的化合物： 或其盐，其中 R1 是氢原子或类似物；R2 是 NHSO2R3 或类似物；R3 是(C1-C6)烷基或类似物；R5 是氢原子或类似物；R6 和 R7 可以相同或不同，且各自独立地代表氢原子或类似物；X 是氧原子或类似物；Y 是氧原子或类似物；Z1 至 Z6 是碳原子或类似物；n 是 0 至 6 的整数；*1 是不对称碳原子；当 R5 不是氢原子时，*2 是不对称碳原子。
• Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β₃-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects
  作者：Yasuhiro Wada、Hiromitsu Shirahashi、Taisuke Iwanami、Masami Ogawa、Seiji Nakano、Akifumi Morimoto、Ken-ichi Kasahara、Eiichi Tanaka、Yoshio Takada、Shigeki Ohashi、Mutsuhiro Mori、Satoshi Shuto

  DOI：10.1021/acs.jmedchem.5b00638

  日期：2015.8.13

  Novel indazole derivatives were prepared and evaluated for their biological activity and cardiovascular safety profile as human A-adrenergic receptor (AR) agonists. Although the initial hit compound 5 exhibited significant beta(3)-AR agonistic activity (EC50 = 21 nM), it also exhibited agonistic activity at the alpha(1A)-AR (EC50 = 219 nM, selectivity: alpha(1A)/beta(3) = 10-fold). The major metabolite of 5, which was an oxidative product at the indazole 3-methyl moiety, gave a clue to a strategy for improvement of the selectivity for beta(3)-AR agonistic activity versus au-AR agonistic activity. Thus, modification of the 3-substituent of the indazole moiety effectively improved the selectivity to develop compound 11 with potent beta(3)-AR agonistic activity (EC50 = 13 nM) and high selectivity (alpha(1A)/beta(3) = >769-fold). Compound 11 was also inactive toward beta(1) and beta(2)-ARs and showed dose dependent beta(3)-AR mediated relaxation of marmoset urinary bladder smooth muscle, while it did not obviously affect heart rate or blood pressure (iv, 3 mg/kg) in anesthetized rats.